

Macular Blood Flow Changes in Branch Retinal Vein Occlusion Examined by Optical

Coherence Tomography Angiography Variable Interscan Time Analysis

Naomi Nishigori, MD, Yuki Muraoka, MD, PhD, Masaharu Ishikura, MD, Shin Kadomoto, MD, PhD,

Yuki Mori, MD, Shogo Numa, MD, PhD, Tomoaki Murakami, MD, PhD, Sotaro Ooto, MD, PhD,

Akitaka Tsujikawa, MD, PhD

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine,

Kyoto, Japan

Short title: VISTA of macular blood flow in BRVO

Conflicts of Interest: The authors have no actual or potential conflicts of interest to declare.

Funding/Support: This work was supported in part by a grant-in-aid for scientific research (No.

20K09771) from the Japan Society for the Promotion of Science (Tokyo, Japan), Alcon Japan, Ltd.

(Tokyo, Japan), and Canon INC. (Tokyo, Japan). The funders had no role in the study design, data

collection, or analysis, the decision to publish, or preparation of the manuscript.

Financial Disclosures: None of the authors has proprietary interest in any product described in the article. The authors report the following relationships: N. Nishigori: None; Y. Muraoka: Bayer Yakuhin, Novartis Pharma, Canon, Santen Pharmaceutical, Senju Pharmaceutical, Bayer Yakuhin, Novartis Pharma; M. Ishikura: none; N. S. Kadomoto: Canon, Santen Pharmaceutical, Senju Pharmaceutical, Japan Focus; Y. Mori: Santen Pharmaceutical; S. Numa; Senju Pharmaceutical; T. Murakami: Bayer Yakuhin, Kowa Pharmaceutical, Alcon Pharma, Novartis Pharma, Santen Pharmaceutical, Senju Pharmaceutical; S. Ooto: Bayer Yakuhin, Kowa Pharmaceutical, Alcon Pharma, Janssen Pharmaceutical, Novartis Pharma, AMO Japan, Santen Pharmaceutical, Alcon Japan, Senju Pharmaceutical, Japan Focus; A. Tsujikawa: Canon, Findex, Santen Pharmaceutical, Kowa Pharmaceutical, Pfizer, AMO Japan, Senju Pharmaceutical, Wakamoto Pharmaceutical, Alcon Japan, Alcon Pharma, Otsuka Pharmaceutical, Tomey Corporation, Taiho Pharma, Hoya, Bayer Yakuhin, Novartis Pharma, Chugai Pharmaceutical, Astellas, Eisai, Daiich-Sankyo, Janssen Pharmaceutical, Kyoto Drug Discovery & Development, Allergan Japan, MSD, Ellex, Sanwa Kagaku Kenkyusho, Nitten Pharmaceutical, AbbVie GK.

Address correspondence to: Yuki Muraoka, MD, PhD

Department of Ophthalmology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto

606-8507, Japan. E-mail: muraoka@kuhp.kyoto-u.ac.jp

Key Words: Branch retinal vein occlusion, interscan time, macular edema, optical coherence

tomography, variable interscan time analysis

Summary Statement

Performing variable interscan time analysis in optical coherence tomography angiography on eyes

with branch retinal vein occlusion enabled the detection of macular perfusion changes that were

undetectable using the standard interscan times and might be predictive of the recurrence of macular

edema.

Abstract

Purpose: To examine the relationship between changes in retinal blood flow and the recurrence of macular edema in eyes with branch retinal vein occlusion (BRVO).

Methods: This observational study included 32 eyes in 32 patients (18 men and 14 women) with BRVO who visited the Department of Ophthalmology at Kyoto University Hospital (February 2021–November 2021). At the time of inclusion in the study, each patient underwent optical coherence tomography angiography (OCTA) on a macular area measuring $4 \times 4 \text{ mm}^2$. For variable interscan time analysis (VISTA), different interscan times were set at 7.6 (IST_{7.6}) and 20.6 ms (IST_{20.6}) for the OCTA. The parafoveal vessel densities were measured sectorally at IST_{7.6} and IST_{20.6}, and their relationship with the longitudinal changes evident in the retinal thicknesses during the VISTA examination and 2 months later was evaluated.

Results: The parafoveal vessel densities in the affected sector was significantly greater at IST_{20.6} than at IST_{7.6} ($P=0.011$). At 2 months after the VISTA examination, 6 patients (19%) showed recurrence of macular edema involving the fovea. The difference in the parafoveal vessel densities (IST_{20.6} – IST_{7.6}) in the affected sector was significantly associated with longitudinal retinal thickening in the corresponding parafovea ($P=0.020$) and fovea ($P=0.014$).

Conclusions: In eyes with BRVO, OCTA VISTA facilitated the detection of retinal blood flow changes that might be predictive for the recurrence of macular edema.

INTRODUCTION

Retinal vein occlusion (RVO) is one of the most common retinal vascular diseases.¹⁻³ RVO is often accompanied by macular edema (ME) and concomitant visual disturbances.¹ The ME associated with RVO can be ameliorated using anti-vascular endothelial growth factor (VEGF) treatments.⁴⁻⁷ However, blockade of VEGF does not act on thrombus formation in the affected retinal veins, and the ME can recur if an intravitreal level of the anti-VEGF agent is decreased. It is also clinically difficult to predict the recurrence of ME.⁸

Until recently, the evaluation of retinal circulation was commonly performed using fluorescein angiography (FA). However, it is now more common to use optical coherence (OCT) angiography (OCTA) in clinical research and practice. OCTA visualizes retinal blood flow by extracting decorrelation signals that change among multiple OCT-B scans acquired at the same location; this facilitates detection of retinal nonperfusion, microaneurysms, and collateral vessels in eyes with RVO.⁹⁻¹³ In contrast, it has also been reported that OCTA does not detect all of the lesions delineated by FA;¹⁴ this may be related to the association between the blood flow velocity and interscan time (IST) of OCTA.¹⁵⁻¹⁷ If the blood flow velocity is below the detection threshold of the IST, it theoretically cannot be visualized by OCTA.

In OCTA, a method to detect abnormal blood flow was recently developed; it utilizes changing ISTs and is called variable IST analysis (VISTA).¹⁸ Using VISTA, novel findings in diabetic retinopathy¹⁹ and age-related macular degeneration (AMD)^{20,21} were recently reported. If the VISTA technique can be applied to eyes with RVO, it might be possible to identify novel findings that are undetectable by conventional OCTA. However, researchers have not applied VISTA for eyes with RVO. Therefore, in this study, we used our VISTA protocol to study patients with branch RVO (BRVO) by examining their macular perfusion status and analyzing the changes in their retinal morphology.

METHODS

Patients and Methods

This observational study was approved by the Institutional Review Board of Kyoto University Graduate School of Medicine (Kyoto, Japan), and it adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from each subject before any study procedures or examinations.

We included patients with BRVO lasting more than six months in duration who visited the Department of Ophthalmology, Kyoto University Hospital between February 2021 and November 2021. We excluded eyes with multiple retinal vein occlusions, BRVO located more to the nasal side than the optic disc, central RVO, hemi-central RVO, co-existing ocular disease (diabetic retinopathy, hypertensive retinopathy, retinal arterial occlusion, retinal arterial macroaneurysm, glaucoma, retinitis pigmentosa, AMD), keratoconus, high myopia (more severe than -6 diopters), and/or high astigmatism (more severe than ± 3 diopters). We also excluded eyes with poor-quality OCTA images (signal strength index of < 6) caused by eye movement or media opacities.

At the initial visit, all the patients were treatment-naïve and showed visual disturbance due to retinal hemorrhage and edema involving the fovea. The symptom duration was less than 3 months before the initial visit. The patients initially received intravitreal injections of ranibizumab (Lucentis, 0.5 mg/0.05 mL; Novartis Pharma AG; Basel, Switzerland) for the treatment of ME and/or serous retinal detachment at the fovea. None of the patients received treatment other than ranibizumab (e.g., bevacizumab or aflibercept injection, grid laser photocoagulation, steroid treatment, surgical intervention). After the initial injections, pro re nata injections were performed only when the ME or serous retinal detachment was evident at the fovea on OCT images and the patient's informed consent could be obtained. For each patient, the same anti-VEGF agent was used for the initial and subsequent injections.

Eventually, 32 eyes of 32 consecutive patients (18 men and 14 women) with BRVO met the criteria and were included in the study. At the inclusion, the ME and retinal hemorrhage were substantially absorbed within the fields of OCTA views. Even if ME was present, its severity was insufficient to affect image quality.

VISTA in OCTA

At the time of inclusion in the study, each patient underwent high-resolution spectral domain OCTA (OCT-A1, Canon Inc., Tokyo, Japan) in addition to routine examinations that included measurement of the best-corrected visual acuity (BCVA) using a Landolt chart, measurement of the intraocular pressure, slit-lamp biomicroscopy, and OCT.

For OCTA images, a foveal area ($4 \times 4 \text{ mm}^2$; 464×464 pixels) was imaged in the rescan mode, where the scanner once captures the area from top to bottom and then goes back to rescan only the area that could not to be captured in the first scan.

For OCTA VISTA, a macular area was first scanned using an IST of 7.6 ms ($\text{IST}_{7.6}$) and then scanned using an IST of 20.6 ms ($\text{IST}_{20.6}$) in a repeat mode. This mode enables identical areas to be captured when the ISTs are changed. The patients were imaged three times at each IST, and averaged OCTA images were generated.

Quantitative Measurements in OCTA VISTA

For measuring parafoveal vessel densities (VD), the device's built-in software was used to binarize the averaged OCTA images for the entire retina slab. The center of an Early Treatment Diabetic Retinopathy Study (ETDRS) grid was set on the center of the fovea without any rotation (Figure 1). For each subfield in the inner (1–3 mm) ring of the ETDRS grid, the parafoveal VD was calculated as the ratio of the area occupied by the vessels to the total area (Figure 1). A color map of VD was created using the device's built-in software (Figure 1). These procedures were performed using the OCTA images acquired at $\text{IST}_{7.6}$ and $\text{IST}_{20.6}$.

Longitudinal Thickness Changes in the Fovea and Parafovea

At the time of the VISTA examination and 2 months afterward, we acquired macular volume scans using spectral domain OCT (Spectralis HRA + OCT, Heidelberg Engineering; Heidelberg, Germany) and created whole-retinal thickness maps centered on the fovea. In the ETDRS grid, the foveal thickness was defined as the averaged retinal thickness in the central grid; the parafoveal thickness

was defined as the averaged retinal thickness in each sector of the inner ring. Retinal thickness calculations for each grid were performed using the manufacturer's built-in software (Spectralis Acquisition and Viewing Modules, version 6.0; Heidelberg Engineering). The changes in the longitudinal thickness of the parafovea and fovea were evaluated, and their relationship with the differences in the parafoveal VDs between IST_{20.6} and IST_{7.6} were examined.

Statistical Analysis

Statistical analyses were performed using JMP 16 (SAS Institute Inc., Cary, NC, USA). All values are presented as the mean $\pm$ standard deviation. The parafoveal VDs acquired at IST_{7.6} and IST_{20.6} were compared for each sector using the paired t-test. The sectorial differences between the parafoveal VDs (IST_{20.6} – IST_{7.6}) were compared using one-way analysis of variance and Tukey's HSD test. A multivariate regression analysis was performed to evaluate the contribution of the parafoveal VDs differences (IST_{20.6} – IST_{7.6}) to the changes in foveal thickness. Statistical significance was set at $P < 0.05$.

RESULTS

At the initial visit, all patients showed visual disturbance because of ME and/or serous retinal detachment (Table 1); the mean logMAR BCVA was 0.17 ± 0.25 (Snellen equivalent: 20/200–20/13), and the mean foveal thickness was 471.8 ± 126.1 μm . At the OCTA VISTA examination, the mean logMAR BCVA improved to -0.05 ± 0.13 (Snellen equivalent: 20/40–20/12), and the foveal thickness decreased to 278.9 ± 57.5 μm ; both of these had improved significantly since the initial visit ($P < 0.001$ for each, Table 1).

Parafoveal VD examined by OCTA VISTA

Supplemental Digital Content 1 (see Table) shows the mean parafoveal VDs for IST_{7.6} and IST_{20.6}. In the affected sector, the mean parafoveal VD at IST_{20.6} was significantly greater than that at IST_{7.6} ($P = 0.011$). The mean difference in the parafoveal VD in the affected sector was significantly greater

than that in the unaffected ($P=0.002$) and nasal sectors ($P=0.006$) (Figure 2). In 14 patients (43%), the parafoveal capillaries including collateral vessels and microaneurysms were lowly reflective, and the delineations were poor on the OCTA images at $IST_{7.6}$; these were more reflective and more clearly delineated at $IST_{20.6}$ (Figure 3; Supplemental Digital Content 2 (see Supplemental Figure) showing a BRVO-associated microaneurysm whose delineation is altered in the VISTA).

Association between VISTA findings and Future Retinal Thickening

At 2 months after the VISTA examination, 6 patients (19%) exhibited recurrence of the ME involving the fovea. The differences in the parafoveal VDs ($IST_{20.6} - IST_{7.6}$) of the affected and nasal sectors were significantly associated with parafoveal thickening in the corresponding sectors ($P=0.020$, $P=0.011$, respectively) (Table 2, Figures 3 and 4). In addition, the difference between $IST_{20.6}$ and $IST_{7.6}$ in the parafoveal VD of affected sector was significantly associated ($P=0.014$) with foveal thickening (Table 2, Figures 3 and 4).

DISCUSSION

Using a VISTA protocol, we could detect the retinal blood flow changes in eyes with BRVO; these could not be imaged well using conventional OCTA alone. In addition, we identified that the parafoveal circulatory changes in affected sector were associated with the retinal thickening in the corresponding parafovea and the fovea.

The relationship between macular nonperfusion and ME has been somewhat controversial in eyes with RVO.²²⁻²⁴ Yoo et al²² suggested that larger area of retinal nonperfusion might be a risk factor for ME recurrence. In contrast, Finkelstein²³ showed that macular nonperfusion might contribute to the spontaneous resolution of ME and a better concomitant visual outcome. We suggest that the inconsistencies in the previous reports might have resulted from variations in the assessments of the retinal nonperfusion. On FA for eyes with RVO, the assessment of retinal nonperfusion (capillary drop out) is difficult because the affected retinal areas often experience dye leakage, which limits image resolution and contrast.

Retinal vascular changes can be evaluated more clearly and objectively using OCTA because it is not susceptible to dye leakage and it has a higher resolution. OCTA might be a more suitable than FA for the evaluation of the capillary changes associated with RVO. However, researchers have reported that microaneurysms that were detectable on FA could not always be delineated on OCTA. FA visualizes retinal vasculatures based on the dye (plasma) dynamics; OCTA is based on erythrocyte dynamics. The difference in imaging mechanisms may relate to the detection rate of the retinal vascular changes; it is possible that the retinal blood flow is too slow to be visualized using an IST in the default setting.

Choi and Moulton et al¹⁸ recently developed the VISTA technique for OCTA, which enables capture of the relative blood flow speed by shortening the IST from the default setting to 1.5 ms and 3 ms. Using their VISTA protocol, new findings were identified in diabetic retinopathy¹⁹ and AMD (polypoidal choroidal vasculopathy, and geographic atrophy).^{20,21} In contrast, our VISTA protocol differed from that of previous reports and was a new attempt to delineate slowed blood flow by extending the IST from 7.6 ms to 20.6 ms. Our VISTA protocol facilitated detection of the slowed retinal blood flow in affected sector (Figures 2, 3 and Supplemental Digital Content 1); this was found to be significantly associated with future retinal thickening in the corresponding parafovea and fovea (Figures 3, 4 and Table 2).

In this study, ME subsequently recurred in some patients whose parafoveal VD at IST_{7.6} in the affected sector was slightly low and the difference in the parafoveal VDs (IST_{20.6} – IST_{7.6}) was large (Figure 3, upper panel). In contrast, ME did not recur in other patients whose parafoveal VD at IST_{7.6} was quite low and the difference in the parafoveal VDs (IST_{20.6} – IST_{7.6}) was almost none (Figure 4, upper panel). Previous reports have shown that the larger macular nonperfusion area (NPA) may contribute to the resolution of ME.^{11,12,23} In this study, some cases with low parafoveal VD at IST_{7.6} in the affected sector had large macular NPA in the corresponding parafovea. In such cases, the parafoveal VDs at IST_{20.6} did not increase, and the differences in the parafoveal VDs (IST_{20.6} – IST_{7.6}) were faint. A lower parafoveal VD at IST_{7.6} does not always imply large differences in the parafoveal VDs (IST_{20.6} – IST_{7.6}).

The retinal vasculature that was detectable using our VISTA protocol might cause tissue hypoxia and upregulation of VEGF, which could increase vascular permeability and retinal exudative changes. Using conventional OCTA (without VISTA) for eyes with BRVO, Kogo et al¹³ reported that the sectoral vessel dilation (increased vessel diameter index) at the parafovea was positively associated with ME, similar to the current VISTA finding. Using an adaptive optics scanning laser ophthalmoscope and a retinal function imager, the blood flow velocities of the capillaries and venules at the human macula have been found to be 1.34–1.49 mm/sec,^{25,26} and 2.82–3.70 mm/sec,²⁷ respectively. In contrast, the lowered thresholds for blood flow velocity measurement at IST_{7.6} and IST_{20.6} in our VISTA protocol provided calculations of approximately 1.13 mm/sec, and 0.42 mm/sec, respectively ($4000 / 464 = 8.62 \text{ um/pixel}$, $v [\text{mm/sec}] = 8.62 / \text{IST}$). Thus, the range of the blood flow velocities of the newly detectable vessels in our VISTA protocol (enabled by extending the IST from 7.6 ms to 20.6 ms) is estimated to be 0.42–1.13 mm/sec. Combined with the results of previous reports, we suggest that the VISTA results of this study demonstrated that an increase in the parafoveal VD (IST_{20.6} – IST_{7.6}) is a good representation of how congestive blood flow is affected by BRVO.

In the current study, the delineation of most abnormal vessels that morphologically appeared to be collateral vessels was hardly altered in the extension of IST. However, in a few collateral vessels, the parafoveal VD at IST_{20.6} was slightly greater than that at IST_{7.6}, and their delineation was enhanced in the extension of the IST. In such vessels, the blood flow may be congestive. Further studies are needed to examine the association between the morphologic and functional changes in the collateral vessels and the recurrence of ME.

There are several limitations to the study that should be considered. The first and major limitation is that this was not a prospective study; the timing of the OCTA VISTA, duration after the onset, follow-up period, and the number of treatments varied among patients. Another possible limitation may be that the number of patients included was small, although some of the results were statistically significant. The third limitation is that the VISTA requires more imaging time compared to the conventional OCTA. It takes approximately 4 s to obtain OCTA images at IST_{7.6} and

approximately 12 s at IST_{20.6}. As extension of the IST may possibly be associated with a risk of poor fixation, which may result in poorer image quality, care should be taken to minimize the imaging time. However, the OCTA used in this study is equipped with a mode to automatically rescan the area that could not be captured in the first scan. Furthermore, speckle noise of the OCTA images could be sufficiently reduced by averaging three OCTA images. We considered that the image qualities of the OCTA obtained at IST_{7.6} were equivalent to those that were obtained at IST_{20.6}. Despite these limitations, our VISTA protocol successfully detected slowed retinal blood flow at the parafovea, which was not detectable using the default settings. Moreover, the perfusion changes at the parafovea were found to contribute to the future development of the ME. The OCTA device used in this study is commercially available, and most of the results were analyzed automatically using the manufacturer's built-in software, which is considered highly reliable.

Our VISTA protocol might also be applicable for examining the macular perfusion status in eyes with central RVO or retinal vascular diseases other than RVO. Further prospective studies with larger cohorts are necessary to confirm our VISTA findings.

REFERENCES

1. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. *Ophthalmology* 2010; 117:1094-1101.
2. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. *Ophthalmology* 2011; 118:119-133.
3. Hayreh SS, Zimmerman MB. Branch retinal vein occlusion: natural history of visual outcome. *JAMA Ophthalmol* 2014; 132:13-22.

4. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology* 2010; 117:1102-1112.
5. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology* 2010; 117:1124-1133.
6. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. *Ophthalmology* 2014; 121:202-208.
7. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. *Ophthalmology* 2015; 122:538-544.
8. Yasuda S, Kondo M, Kachi S, et al. Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion. *Retina* 2011; 31:1075–1082.
9. Kashani AH, Lee SY, Moshfeghi A, et al. Optical coherence tomography angiography of retinal venous occlusion. *Retina* 2015; 35:2323–2331.

10. Tsuboi K, Ishida Y, Kamei M. Gap in capillary perfusion on optical coherence tomography angiography associated with persistent macular edema in branch retinal vein occlusion. *Invest Ophthalmol Vis Sci* 2017; 58:2038-2043.
11. Hasegawa T, Takahashi Y, Maruko I, et al. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion. *Br J Ophthalmol* 2019; 103:1367-1372.
12. Hasegawa T, Murakawa S, Maruko I, et al. Correlation between reduction in macular vessel density and frequency of intravitreal ranibizumab for macular oedema in eyes with branch retinal vein occlusion. *Br J Ophthalmol* 2019; 103:72-77.
13. Kogo T, Muraoka Y, Uji A, et al. Angiographic risk factors for recurrence of macular edema associated with branch retinal vein occlusion. *Retina* 2021; 41:1219–1226.
14. Tokayer J, Jia Y, Dhalla AH, et al. Blood flow velocity quantification using split-spectrum amplitude-decorrelation angiography with optical coherence tomography. *Biomed Opt Express* 2013; 4:1909-1924.
15. Hamada M, Ohkoshi K, Inagaki K, et al. Visualization of microaneurysms using optical coherence tomography angiography: comparison of OCTA en face, OCT B-scan, OCT en face, FA, and IA images. *Jpn J Ophthalmol* 2018; 62:168-175.

16. Miwa Y, Murakami T, Suzuma K, et al. Relationship between functional and structural changes in diabetic vessels in optical coherence tomography angiography. *Sci Rep* 2016; 6:29064.
17. Couturier A, Mane V, Bonnin S, et al. Capillary plexus anomalies in diabetic retinopathy on optical coherence tomography angiography. *Retina* 2015; 35:2384-2391.
18. Ploner SB, Moulton EM, Choi W, et al. Toward quantitative OCT angiography: visualizing flow impairment using variable interscan time analysis (VISTA). *Retina* 2016; 36:118-126.
19. Arya M, Filho MB, Rebhun CB, et al. Analyzing relative flow speeds in diabetic retinopathy using variable interscan time analysis OCT angiography. *Ophthalmol Retina* 2021; 5:49-59.
20. Choi W, Moulton EM, Waheed NK, et al. Ultrahigh-speed, swept-source optical coherence tomography angiography in nonexudative age-related macular degeneration with geographic atrophy. *Ophthalmology* 2015; 122:2532-2544
21. Rebhun CB, Moulton EM, Novais EA, et al. Polypoidal choroidal vasculopathy on swept-source optical coherence tomography angiography with variable interscan time analysis. *Transl Vis Sci Technol* 2017; 6:4.
22. Yoo JH, Ahn J, Oh J, et al. Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection. *Br J Ophthalmol* 2017; 101:1334-1339.

23. Finkelstein D. Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. *Arch Ophthalmol* 1992; 110:1427–1434.
24. Sakimoto S, Kamei M, Suzuki M, et al. Relationship between grades of macular perfusion and foveal thickness in branch retinal vein occlusion. *Clin Ophthalmol* 2013; 7:39-45.
25. Uji A, Hangai M, Ooto S, et al. The source of moving particles in parafoveal capillaries detected by adaptive optics scanning laser ophthalmoscopy. *Invest Ophthalmol Vis Sci* 2012; 53:171-178.
26. Noma H, Funatsu H, Sakata K, et al. Macular microcirculation and macular oedema in branch retinal vein occlusion. *Br J Ophthalmol* 2009; 93:630-633.
27. Wang L, Jiang H, Grinvald A, et al. A mini review of clinical and research applications of the retinal function imager. *Curr Eye Res* 2018; 43:273-288.

FIGURE LEGENDS

Figure 1. Quantitative sectoral evaluations of the macular retinal vasculature using optical coherence tomography angiography (OCTA) for patients with branch retinal vein occlusion

A: Averaged OCTA images of the macular area, with a scanning area of $4 \times 4 \text{ mm}^2$

B: Binarized OCTA image. On the binarized image, the parafoveal vessel density (VD) is calculated as the ratio of the area occupied by the vessels to the total area of each sector.

C: The VD color map made by the device's software. These procedures (A–C) were performed using OCTA images acquired at ISTs of 7.6 ms and 20.6 ms for each patient.

Figure 2. Comparisons of sector differences in the parafoveal vessel densities (VD) examined by variable interscan time analysis (VISTA)

In the VISTA, the difference in the parafoveal VD (calculated as the difference between the value measured using an interscan time of 20.6 ms minus that of an interscan time of 7.6 ms) in the affected sector was significantly greater than those in the unaffected and nasal sectors. *: significant difference

Figure 3. Two representative cases with recurrence of branch retinal vein occlusion (BRVO)-associated macular edema examined by variable inter scan time analysis (VISTA)

A–D: A 73-year-old woman with inferotemporal BRVO in the left eye. **A, B:** Optical coherence tomography (OCT) angiography (OCTA) acquired using interscan times (IST) of 7.6 ms (**A**) and 20.6 ms (**B**). **C, D:** OCT retinal thickness maps. At the initial visit, the Snellen visual acuity (VA) was 20/32. The patient received four anti-vascular endothelial factor (VEGF) treatments for the macular edema before the VISTA examination. At the VISTA examination (**A–C**), the macular edema is substantially resolved, and the Snellen VA improved to 20/12. The comparison between the OCTA images taken using ISTs of 20.6 ms (**B**) and 7.6 ms (**A**) shows that the parafoveal VDs increased in the affected and nasal sectors. Two months after the therapy (**D**), the macular edema recurred in the inferonasal parafovea where the parafoveal VD increased in the VISTA.

E–H: A 70-year-old man with superotemporal BRVO in the left eye. **E, F:** OCT angiograms obtained using an IST of 7.6 ms (**E**) and 20.6 ms (**F**). **G, H:** OCT retinal thickness maps. At the initial visit, the Snellen VA was 20/50. The patient received six anti-VEGF treatments for the macular edema before the VISTA examination. At the VISTA examination (**E–G**), the macular edema was substantially resolved, and the Snellen VA improved to 20/12. A comparison between the images taken using ISTs of 20.6 ms (**F**) and 7.6 ms (**E**) shows that the parafoveal VD increased in the affected sector. Two months after the therapy (**H**), the macular edema recurred in the upper parafovea where the parafoveal VD increased in the VISTA.

Figure 4. Two representative cases without recurrence of branch retinal vein occlusion (BRVO)-associated macular edema examined by variable inter scan time analysis (VISTA).

A–D: A 57-year-old woman with inferotemporal BRVO in the right eye. **A, B:** Optical coherence

tomography (OCT) angiograms obtained using an interscan time (IST) of 7.6 ms (**A**) or 20.6 ms (**B**).

C, D: OCT retinal thickness maps. At the initial visit, the Snellen visual acuity (VA) was 20/200. The

patient received four anti-vascular endothelial factor (VEGF) treatment for the macular edema before

the VISTA examination. At the VISTA examination (**A–C**), the macular edema is substantially

resolved, and the Snellen VA improved to 20/15. A comparison between images taken using ISTs of

20.6 ms (**B**) and 7.6 ms (**A**) shows that the parafoveal VDs do not increase in the any parafoveal

sectors. Two months after the VISTA examination (**D**), the macular edema had not recurred.

E–H: A 63-year-old man with inferotemporal BRVO in the right eye. **E, F:** OCT angiograms obtained

using ISTs of 7.6 ms and 20.6 ms (**F**). **G, H:** OCT retinal thickness maps. At the initial visit, the

Snellen visual acuity was 20/200. The patient received three anti-VEGF treatments for the macular

edema before the VISTA examination. At the VISTA examination (**E–G**), the macular edema is

substantially resolved, and the Snellen VA improved to 20/12. The comparison between images

obtained using ISTs of 20.6 ms (**F**) and 7.6 ms (**E**) shows that the parafoveal VD did not increase in

the any parafoveal sectors. Two months after the VISTA examination (**H**), the macular edema had not recurred.

Table 1. Characteristics of included patients with branch retinal vein occlusion

Number of patients included (men/women)	18/14
Age (years)	68.3 ± 12.8
Systemic hypertension, (n)	18
Diabetes mellitus, (n)	5
Hyperlipidemia, (n)	10
At initial visit	
Mean logMAR visual acuity	0.17 ± 0.25
(range in Snellen equivalent)	20/200–20/12
Mean foveal thickness (μm)	471.8 ± 126.1
Time from onset to OCTA examination (months)	47.6 ± 37.2
Mean logMAR visual acuity	-0.05 ± 0.13
(range in Snellen equivalent)	20/40–20/12
Mean foveal thickness (μm)	278.9 ± 57.5
Number of ranibizumab injections required	4.2 ± 4.1
BRVO, branch retinal vein occlusion; logMAR, logarithm of the minimal angle of resolution; OCTA, optical coherence tomography angiography; Data are mean ± standard deviation unless otherwise indicated.	

Table 2. Association between differences in parafoveal vessel densities examined with IST of 20.6 msec and those with IST of 7.6 msec and retinal thickness changes in the corresponding parafovea and fovea

	Corresponding parafovea		Fovea	
	R	<i>P</i> value*	β	<i>P</i> value †
Affected	0.409	0.020	0.454	0.014
Unaffected	0.130	0.477	0.151	0.406
Nasal	0.442	0.011	0.079	0.776
Temporal	0.114	0.543	0.079	0.769

VD = vessel density; IST = interscan time. *Univariate linear regression analysis was performed to evaluate the contribution of the parafoveal vasculature to the corresponding parafovea thickness changes. † A multivariate regression analysis was performed to evaluate the contribution of the parafoveal vasculature to the foveal thickness changes.




Figure 1




Figure 2




Figure 3




Figure 4

SUPPLEMENTAL MATERIALS

Supplemental Digital Content 1. A supplementary table showing comparison of the parafoveal vessel densities of eyes with branch retinal vein occlusion using variable interscan time analysis of optical coherence tomography angiography

Supplemental Digital Content 2. A branch retinal vein occlusion (BRVO)-associated microaneurysm whose delineation is altered in the variable interscan time analysis (VISTA)

A representative case of a 70-year-old man had superotemporal BRVO in the left eye.

A, B: The optical coherence tomography (OCT) angiography (OCTA) acquired using interscan times (ISTs) of 7.6 ms (**A**) and 20.6 ms (**B**). **C, D:** The magnified parts of the microaneurysm on OCT angiograms **A**, and **B**, respectively. The OCT angiograms obtained using ISTs of 7.6 ms (**A** and **C**) show that the reflectivities of the microaneurysm are heterogeneous. In contrast, the reflectivities of the microaneurysm become homogeneous on the OCT angiograms obtained using an IST of 20.6 ms (**B** and **D**). At 2 months after the OCT angiography examination, the retinal thickening around the microaneurysm is remarkable, and the delineation is altered in the VISTA.


Supplemental Table 1. Comparison of the parafoveal vessel densities of eyes with branch retinal vein occlusion using variable interscan time analysis of optical coherence tomography angiography

Sector	Parafoveal vessel density		<i>P</i> value
	IST _{7.6}	IST _{20.6}	
Affected	39.2 ± 6.1	40.5 ± 5.6	0.011
Unaffected	41.4 ± 2.9	40.4 ± 3.7	0.059
Nasal	42.1 ± 3.2	41.4 ± 3.1	0.063
Temporal	42.5 ± 3.5	42.9 ± 3.5	0.271

IST_x = interscan time of *x* msec.

Comparisons of the parafoveal vessel densities in variable interscan time analysis were performed using a paired *t* test.

Supplemental Digital Content 1



Supplemental Digital Content 2

This is a non-final version of an article published in final form in RETINA.

<https://doi.org/10.1097/iae.00000000000003596>

